326,126 Shares in Neuronetics, Inc. (NASDAQ:STIM) Purchased by CenterBook Partners LP

CenterBook Partners LP acquired a new stake in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 326,126 shares of the company's stock, valued at approximately $1,200,000. CenterBook Partners LP owned approximately 0.50% of Neuronetics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of STIM. Balyasny Asset Management L.P. boosted its stake in Neuronetics by 29.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock valued at $2,386,000 after acquiring an additional 337,539 shares in the last quarter. Nkcfo LLC acquired a new stake in shares of Neuronetics in the 1st quarter worth $460,000. Assenagon Asset Management S.A. acquired a new stake in shares of Neuronetics in the 1st quarter worth $359,000. Citizens Financial Group Inc. RI acquired a new stake in shares of Neuronetics in the 1st quarter worth $305,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in Neuronetics in the first quarter worth about $254,000. Institutional investors own 53.59% of the company's stock.

Insiders Place Their Bets

In related news, EVP Stephen Furlong sold 193,460 shares of the company's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the transaction, the executive vice president owned 416,593 shares in the company, valued at $1,778,852.11. This represents a 31.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.70% of the company's stock.

Neuronetics Stock Up 6.4%

NASDAQ STIM traded up $0.23 during trading on Thursday, hitting $3.83. The company's stock had a trading volume of 1,186,849 shares, compared to its average volume of 848,716. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.44 and a quick ratio of 2.28. The company has a market cap of $253.20 million, a PE ratio of -2.92 and a beta of 1.85. The business's 50 day simple moving average is $3.77 and its 200-day simple moving average is $3.72. Neuronetics, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative return on equity of 174.15% and a negative net margin of 53.67%. The company had revenue of $31.98 million for the quarter, compared to analyst estimates of $29.07 million. On average, equities analysts anticipate that Neuronetics, Inc. will post -1.13 EPS for the current fiscal year.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.